Scarica l'app Stockscreener
27.54
3.33%
-0.95
Dopo l'orario di chiusura:
27.62
0.08
+0.29%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$28.49
Aprire:
$28.49
Volume 24 ore:
8.34M
Relative Volume:
0.83
Capitalizzazione di mercato:
$10.72B
Reddito:
$3.14B
Utile/perdita netta:
$-3.36B
Rapporto P/E:
-3.1546
EPS:
-8.73
Flusso di cassa netto:
$-4.03B
1 W Prestazione:
+8.72%
1M Prestazione:
+9.55%
6M Prestazione:
+9.68%
1 anno Prestazione:
-54.25%
Intervallo 1D:
$27.48
$28.67
Intervallo di 1 settimana:
$24.56
$28.99
Portata 52W:
$23.15
$60.65
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Confronta MRNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
27.54 | 11.08B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
402.90 | 103.40B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.48 | 63.59B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.82B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
787.94 | 48.96B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
344.53 | 37.77B | 4.56B | -176.77M | 225.30M | -1.7177 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
Moderna (MRNA) COVID-19 Booster Recommendations Updated by CDC - GuruFocus
CDC adopts individual-based decision-making for COVID-19 shots (MRNA:NASDAQ) - Seeking Alpha
Moderna - WCIV
Will Moderna Inc. see short term momentum2025 Year in Review & Fast Moving Stock Trade Plans - newser.com
Key metrics from Moderna Inc.’s quarterly data2025 EndofYear Setup & Step-by-Step Swing Trade Plans - newser.com
Day 5 of Gains Streak for Moderna Stock with 16% Return (vs. -31% YTD) [10/3/2025] - Trefis
Moderna Inc. (MRNA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans - Greenville Online
Moderna Says GSK ‘Abusing’ Patents to Siphon Covid Shot Profits - Bloomberg Law News
How to interpret RSI for Moderna Inc. stockMarket Risk Analysis & Smart Allocation Stock Reports - newser.com
Moderna (MRNA) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
The CDC still hasn't issued COVID vaccine guidelines, leaving access in limbo - NPR
What to know about this fall’s COVID-19 vaccine - The Globe and Mail
November 14th Options Now Available For Moderna (MRNA) - Nasdaq
6 Healthcare Stocks Positioned to Soar After Trump-Pfizer Deal - Investing.com
Could MRNA's Upcoming Product Launches Reduce COVID Sales Dependency? - The Globe and Mail
Moderna (MRNA) Recently Broke Out Above the 50-Day Moving Average - Yahoo Finance
Union Bancaire Privee UBP SA Sells 15,518 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. $MRNA Shares Sold by Public Employees Retirement System of Ohio - MarketBeat
Brookline Reaffirms Price Target for Moderna (MRNA) After Strong mRNA-1283 Vaccine Results - Yahoo
Moderna Sees Unusually High Options Volume (NASDAQ:MRNA) - MarketBeat
Moderna Opens State-of-the-Art Manufacturing and R&D Facility in the UK - Detroit Free Press
Moderna Stock Is Rallying Wednesday: What's Driving The Action? - Benzinga
Moderna (NASDAQ:MRNA) Shares Up 5.9%Here's Why - MarketBeat
Is Moderna Inc (MRNA) Set to Underperform? Analyzing the Factors Limiting Growth - GuruFocus
Moderna (MRNA) Continues Upward Trend in Early Trading - GuruFocus
What high frequency data says about Moderna Inc.2025 Investor Takeaways & Low Volatility Stock Recommendations - newser.com
mRNA Vaccine and Therapeutics Market to Hit USD 127.8 Billion by 2034, Growing at 10.7% CAGR - openPR.com
Applying chart zones and confluence areas to Moderna Inc.Market Activity Summary & Low Risk High Win Rate Stock Picks - newser.com
Tools to assess Moderna Inc.’s risk profileGDP Growth & Pattern Based Trade Signal System - newser.com
Automated trading signals detected on Moderna Inc.IPO Watch & Weekly Watchlist for Hot Stocks - newser.com
mRNA Market Forecasted to Reach USD 128.6 Billion by 2034, Key Players: Moderna & Pfizer/BioNTech - openPR.com
2 Beaten-Down Stocks to Buy and Hold for a Decade - Yahoo Finance
Chart based exit strategy for Moderna Inc.2025 Market WrapUp & Daily Price Action Insights - newser.com
Moderna, Inc. (MRNA) Stock Analysis: Navigating the 80.69% Potential Upside Amidst Challenges - DirectorsTalk Interviews
Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1 - The Daily Jeffersonian
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2 - The Daily Jeffersonian
Moderna, Inc. Experiences Revision in Stock Evaluation Amid Market Challenges - Markets Mojo
Moderna Announces Data to be Presented at ESMO Congress 2025 - The Daily Jeffersonian
Is Moderna Inc. stock cheap compared to fundamentals2025 Historical Comparison & Consistent Growth Stock Picks - newser.com
Moderna to Present at Upcoming Conferences in June 2025 - Norwich Bulletin
Bank Pictet & Cie Europe AG Grows Holdings in Moderna, Inc. $MRNA - MarketBeat
Moderna (MRNA) Dips More Than Broader Market: What You Should Know - sharewise.com
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.36%
0.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):